Cynbiose receives €1.9 million ($2.1M) to launch CYNBIOME, preclinical excellence network on microbiome and infectious diseases

Cynbiose announces that it has procured financing of €1.9 million ($2.1M) under the third phase of the French Program ‘Investment for the Future’ (PiA3). These funds will make it possible to launch CYNBIOME, the 1st excellence network on microbiome and infectious diseases based on the Non-Human Primate (NHP) model. CYNBIOME is financed by the French government and the Auvergne-Rhône-Alpes region and is supported by Bpifrance (The French Public Bank of Investment). Read the press release January 28, 2020

guillemets gauche Supporting Biomedical Research guillemets droit

Cynbiose is a preclinical Contract Research Organization (CRO) unique in Europe. The company develops and commercializes innovative non human primate (NHP) models to accelerate the preclinical development of drug candidates.

We perform exploratory studies and develop pharmacological models in the main therapeutic areas to bridge the gap between preclinical phase and clinical development.

We provide high value-added services in a quality-based environment and work closely with our customers to achieve long-term relationships.